Finally, the second-generation DNMT inhibitor guadecitabine has been evaluated in a phase 2 trial for patients with advanced HCC who failed prior sorafenib treatment (NCT01752933) and its association with the ICI durvalumab is currently being tested (NCT03257761). The gene discussed is DNMT1; the disease is hepatocellular carcinoma.